Prospective Study Evaluating Clopidogrel Resistance in Ischemic Stroke Patients From Different Ethnicities
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 300
- 主要终点
- Rates of clopidogrel resistance assessed among the different ethnicities
研究概览
简要总结
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent and to be compliant with protocol assessments.
- •Ages 18 and above inclusive
- •Both genders eligible for the study
- •Diagnosis of ischemic cerebrovascular event
排除标准
- •Pregnant patients will be excluded
- •Ages below 18
- •Patients not able to provide informed consent
结局指标
主要结局
Rates of clopidogrel resistance assessed among the different ethnicities
时间窗: 6 months
Identifying of high-risk subgroups of adverse clinical outcomes
时间窗: 6 to 12 months
次要结局
未报告次要终点
研究者
Dr. Najib Dally
Director of Hematology Department
Ziv Hospital